ONC vs. WST: BeOne Medicines vs. West Pharmaceutical Services Stock Comparison
How do BeOne Medicines (ONC) and West Pharmaceutical Services (WST) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BeOne Medicines (ONC) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.
West Pharmaceutical Services (WST) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ONC | WST |
|---|---|---|
| Name | BeOne Medicines Ltd. American Depositary Shares | West Pharmaceutical Services Inc. |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 46.49 billion USD | 27.85 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | February 3, 2016 | March 17, 1980 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ONC | WST |
|---|---|---|
| Total Return (1Y) | 30.59% | 51.68% |
| Total Return (3Y, Annualized) | 30.15% | 7.13% |
| Total Return (5Y, Annualized) | 2.48% | 0.05% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ONC | WST |
|---|---|---|
| Volatility (1Y, Annualized) | 35.90% | 31.45% |
| Beta (5Y) | 0.59 | 1.13 |
| Max Drawdown (5Y) | -68.89% | -59.29% |
| Avg. Volume (3M) | 405.29K | 603.86K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ONC | WST |
|---|---|---|
| Sharpe Ratio (1Y) | 0.73 | 1.51 |
| Sortino Ratio (1Y) | 1.15 | 2.35 |
Profitability
ROE (TTM)
Both BeOne Medicines (ONC) at 18.40% and West Pharmaceutical Services (WST) at 21.23% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.23%
- Max
- 109.18%
- WST
- 21.23%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
West Pharmaceutical Services (WST) at 18.81% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.81%
- WST
- 18.81%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both BeOne Medicines (ONC) at 22.15% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.37%
- Max
- 83.12%
- WST
- 25.37%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ONC | WST |
|---|---|---|
| ROE (TTM) | 18.40% | 21.23% |
| ROA (TTM) | 8.42% | 11.89% |
| Net Margin (TTM) | 13.86% | 18.81% |
| Operating Margin (TTM) | 22.15% | 25.37% |
| Gross Margin (TTM) | 89.39% | 37.59% |
Growth
Revenue Growth
Both BeOne Medicines (ONC) at 40.23% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: West Pharmaceutical Services (WST) reports EPS growth of 1.49%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | ONC | WST |
|---|---|---|
| Revenue Growth (YoY) | 40.23% | 6.25% |
| Revenue Growth (3Y CAGR) | 55.69% | 2.12% |
| EPS Growth (YoY) | -- | 1.49% |
| EPS Growth (3Y CAGR) | -- | -4.23% |
Financial Strength
Current Ratio (MRQ)
Both BeOne Medicines (ONC) at 3.55 and West Pharmaceutical Services (WST) at 2.82 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- WST
- 2.82
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both BeOne Medicines (ONC) at 0.35 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.11
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- WST
- 0.11
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ONC | WST |
|---|---|---|
| Current Ratio (MRQ) | 3.55 | 2.82 |
| Debt / Equity (MRQ) | 0.35 | 0.11 |
| Net Debt / EBITDA | -2.80 | -0.16 |
Dividends
Dividend Yield (TTM)
BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.22%
- WST
- 0.22%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88%
- WST
- 9.88%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ONC | WST |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.22% |
| Dividend Payout Ratio (TTM) | 0.00% | 9.88% |
Valuation
P/E Ratio (TTM)
Both BeOne Medicines (ONC) at 52.17 and West Pharmaceutical Services (WST) at 44.87 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.87
- Max
- 85.34
- WST
- 44.87
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both BeOne Medicines (ONC) at 7.04 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20
- Max
- 58.18
- Q3
- 25.77
- WST
- 8.20
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both BeOne Medicines (ONC) at 7.98 and West Pharmaceutical Services (WST) at 9.40 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.40
- Max
- 13.53
- WST
- 9.40
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ONC | WST |
|---|---|---|
| P/E Ratio (TTM) | 52.17 | 44.87 |
| P/S Ratio (TTM) | 7.04 | 8.20 |
| P/B Ratio (MRQ) | 7.98 | 9.40 |
| Free Cash Flow Yield (TTM) | 2.21% | 1.24% |